LEDIPASVIR AND SOFOSBUVIR (HEPCVIR L) UP TO 37% OFF

LEDIPASVIR AND SOFOSBUVIR (HEPCVIR L) UP TO 37% OFF

DESCRIPTION

  • Composition : ledipasvir and sofosbuvir
  • Manufacturer: Cipla Ltd
  • Indication: Chronic hepatitis C virus (HCV) infection
  • Packaging: bottle of 28 tablets
  • Dosage Form: Tablet

PACKAGE

  • 400mg

Medicine Details

Brand name – Hepcvir L

Generic name – Sofosbuvir/Ledipasvir

Manufacturer – Cipla Ltd.

Salt composition – Ledipasvir (90mg) + Sofosbuvir (400mg)

Storage – Store at room temperature (10-30°C)

Dosage form – Oral (tablet)

Strength – 90mg/400mg

Packaging – Bottle of 28 tablets

Gender – Unisex

Prescription required – Yes

Indication – used in the treatment of Chronic hepatitis C virus (HCV) infection

Description
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) is a combination of two antiviral medications, used in the treatment of chronic (long-lasting) hepatitis C virus (HCV) infection in adults. It is a fixed-dose combination of Ledipasvir and Sofosbuvir. Ledipasvir and Sofosbuvir are the direct-acting antiviral medications. It is an antiviral medicine that works to lower the multiplication of viruses in the body and eliminates the virus from the body over a period of time.

Pharmacodynamics
Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug, that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.

Thorough QT studies have been conducted for Sofosbuvir/Ledipasvir. The effect of Ledipasvir 120 mg twice daily (2.67 times the maximum recommended dosage) for 10 days on QTc interval was calculated in a randomized, multiple-dose, placebo- and active-controlled (moxifloxacin 400 mg), three-period, crossover thorough QT trial in 59 healthy subjects. At the dose of 120 mg twice daily (2.67 times the maximum recommended dosage), Ledipasvir does not prolong QTc interval to any clinically relevant extent. The effect of Sofosbuvir 400 mg (maximum recommended dosage) and 1,200 mg (three times the maximum recommended dosage) on QTc interval was calculated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg), four-period, crossover thorough QT trial in 59 healthy subjects. At a dose three times the maximum recommended dose, Sofosbuvir does not prolong QTc to any clinically relevant extent.

Ingredients
The active ingredient of Hepcvir L is Sofosbuvir/Ledipasvir.

Usage Of Medicine
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) is used in the treatment of Chronic hepatitis C virus (HCV) infection.

Side Effects Of Ledipasvir And Sofosbuvir Tablet

Common Side Effects

  • Headache
  • Nausea
  • Insomnia
  • Fever
  • Chills
  • Muscle pain
  • Cramps
  • Tiredness
  • Serious Side Effects
  • Diarrhea
  • Fainting
  • Loss of appetite
  • Skin rash
  • Itching
  • Irritability

Normal Dose
Take the dose exactly as your healthcare provider directs. Do not crush, break or chew the tablet.

Missed Dose
Take the next scheduled dose if you miss a dose (if it is already the time for your next dose). Do not double the dose strength in order to catch up.

Overdose
In case of overdose, make sure to seek immediate medical support.

  • Tell your healthcare provider about all the medications you already take and your medical history.
  • During pregnancy and breastfeeding, make sure to consult your healthcare provider, before the consumption of Hepcvir L.
  • In patients with liver or/and kidney disease, Hepcvir L should be administered with caution.
  • Avoid consuming alcohol.
  • Do not change the dose strength, unless your healthcare provider tells you.
  • Do not stop taking Hepcvir L tablet, unless your healthcare provider tells you.

DESCRIPTION

  • Composition : ledipasvir and sofosbuvir
  • Manufacturer: Cipla Ltd
  • Indication: Chronic hepatitis C virus (HCV) infection
  • Packaging: bottle of 28 tablets
  • Dosage Form: Tablet

PACKAGE

  • 400mg
Top
    wpChatIcon